397 related articles for article (PubMed ID: 23211492)
1. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B
Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness of high-dose escitalopram in the treatment of patients suffering from schizophrenia with comorbid obsessive-compulsive disorder: an open-label study.
Rubin-Kahana DS; Shelef A; Weizman A; Gothelf D; Timinski I; Spivak B; Stryjer R
Int Clin Psychopharmacol; 2019 Jul; 34(4):179-183. PubMed ID: 31058717
[TBL] [Abstract][Full Text] [Related]
3. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study.
Stryjer R; Budnik D; Ebert T; Green T; Polak L; Weizman S; Spivak B
Clin Neuropharmacol; 2014; 37(3):79-81. PubMed ID: 24824662
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
Ak M; Bulut SD; Bozkurt A; Ozsahin A
Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
[TBL] [Abstract][Full Text] [Related]
6. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
Rabinowitz I; Baruch Y; Barak Y
Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
Denys D; de Geus F; van Megen HJ; Westenberg HG
J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
[TBL] [Abstract][Full Text] [Related]
8. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
[TBL] [Abstract][Full Text] [Related]
9. Obsessive-compulsive disorder: an open-label pilot trial of escitalopram.
Galvão-de Almeida A; Quarantini LC; Góis CR; Santos-Jesus R; Miranda-Scippa AM; de Oliveira IR; da Silva Prado H; Leckman JF; Rosário MC
CNS Spectr; 2007 Jul; 12(7):519-24. PubMed ID: 17603402
[TBL] [Abstract][Full Text] [Related]
10. Citalopram for treatment-resistant obsessive-compulsive disorder.
Pallanti S; Quercioli L; Paiva RS; Koran LM
Eur Psychiatry; 1999 Apr; 14(2):101-6. PubMed ID: 10572334
[TBL] [Abstract][Full Text] [Related]
11. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
Reznik I; Sirota P
J Clin Psychopharmacol; 2000 Aug; 20(4):410-6. PubMed ID: 10917401
[TBL] [Abstract][Full Text] [Related]
12. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases.
Thomsen PH
J Child Adolesc Psychopharmacol; 1997; 7(3):157-66. PubMed ID: 9466233
[TBL] [Abstract][Full Text] [Related]
13. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M
J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845
[TBL] [Abstract][Full Text] [Related]
14. Effect of Ziprasidone Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A 12-Week, Open-Label Uncontrolled Preliminary Study.
Bruno A; Pandolfo G; Cedro C; Gallo G; De Felice M; Zoccali RA; Muscatello MR
Clin Neuropharmacol; 2016; 39(1):6-9. PubMed ID: 26757309
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
[TBL] [Abstract][Full Text] [Related]
16. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Aboujaoude E; Gamel NN
J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
[TBL] [Abstract][Full Text] [Related]
17. Escitalopram prevents relapse of obsessive-compulsive disorder.
Fineberg NA; Tonnoir B; Lemming O; Stein DJ
Eur Neuropsychopharmacol; 2007; 17(6-7):430-9. PubMed ID: 17240120
[TBL] [Abstract][Full Text] [Related]
18. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
[TBL] [Abstract][Full Text] [Related]
19. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
[TBL] [Abstract][Full Text] [Related]
20. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
Pallanti S; Quercioli L; Koran LM
J Clin Psychiatry; 2002 Sep; 63(9):796-801. PubMed ID: 12363120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
